Plain-English translation of NCT04851119 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether , a new drug given through an IV infusion, can help treat children, teens, and young adults whose solid tumors have returned or are no longer responding to standard treatments. The study has two parts: first, doctors will find the right dose of the medication that is safe and effective, and then they will study how well this treatment works against specific types of tumors, including Ewing sarcoma, liver tumors, bone tumors, kidney tumors, and certain other cancers.
Many children and young adults with solid tumors eventually stop responding to standard cancer treatments, and doctors need better options. This trial is testing whether this medication, which works by targeting a specific pathway in cancer cells, can help patients whose tumors have become resistant to other therapies.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the medication as an IV infusion (through a vein) for 4 hours on three days each month, followed by a week of rest—this pattern repeats in 28-day cycles for up to 2 years. You'll have regular check-ups, blood tests, and imaging scans (like X-rays) to monitor how the treatment is working and watch for any side effects. The doctors will also take samples to study how your tumor responds to the medication.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States